The ratings of seven biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Ohr Pharmaceutical Inc (OHRP) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. In Portfolio Grader’s specific subcategories of Earnings Revisions and Equity, OHRP also gets F’s. As of Feb. 10, 2015, 10.7% of outstanding Ohr Pharmaceutical Inc shares were held short. For more information, get Portfolio Grader’s complete analysis of OHRP stock.
The rating of Trius Therapeutics, Inc. (TSRX) slips from a C to a D. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.
Vical Incorporated (VICL) experiences a ratings drop this week, going from last week’s C to a D. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.
This week, Intercept Pharmaceuticals, Inc.’s (ICPT) rating worsens to a D from the company’s C rating a week ago. The stock also gets an F in Equity. As of Feb. 10, 2015, 13.6% of outstanding Intercept Pharmaceuticals, Inc. shares were held short. To get an in-depth look at ICPT, get Portfolio Grader’s complete analysis of ICPT stock.
Tenax Therapeutics, Inc.’s (TENX) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). The stock gets F’s in Earnings Momentum, Earnings Revisions and Equity. Cash Flow and Sales Growth also get F’s. The trailing PE Ratio for the stock is 109.30. For more information, get Portfolio Grader’s complete analysis of TENX stock.
Verastem, Inc. (VSTM) earns an F this week, falling from last week’s grade of D. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. Trade volume is up 662.2% from the previous week. To get an in-depth look at VSTM, get Portfolio Grader’s complete analysis of VSTM stock.
This week, Trevena, Inc. (TRVN) drops from a C to a D rating. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of TRVN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
